Evidence map›Paper›PMID 41817907›Full record

ArticleJournal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing2026

Efficacy and safety of a novel pulsed field ablation system in paroxysmal atrial fibrillation.

Qiming Liu, Hanxiong Liu, Xiaoshu Cheng, Zhihui Zhang, Chenyang Jiang, Zhiyu Ling, Yan Wang, Xuping Li, Zhen Zhang, Qi Chen and 10 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Qiming Liu *The Second Xiangya Hospital of Central South University, Renmin Middle Road 139 #, Changsha, 410011, China.
Hanxiong Liu *The Third People's Hospital of Chengdu, Chengdu, China.
Xiaoshu ChengThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Zhihui ZhangThe Third Xiangya Hospital of Central South University, Changsha, China.
Chenyang JiangSir Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, Hangzhou, China.
Zhiyu LingThe Second Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Yan WangTongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xuping LiThe Second Xiangya Hospital of Central South University, Renmin Middle Road 139 #, Changsha, 410011, China.
Zhen ZhangThe Third People's Hospital of Chengdu, Chengdu, China.
Qi ChenThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Wenzhi LuoThe Third Xiangya Hospital of Central South University, Changsha, China.
Zhenjiang LiuThe Second Xiangya Hospital of Central South University, Renmin Middle Road 139 #, Changsha, 410011, China.
Duan LuoThe Third People's Hospital of Chengdu, Chengdu, China.
Jianhua YuThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Guoshu YangThe Third People's Hospital of Chengdu, Chengdu, China.
Qinmei XiongThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Yan LuoThe Third People's Hospital of Chengdu, Chengdu, China.
Jinzhu HuThe Second Affiliated Hospital of Nanchang University, Nanchang, China.
Juying ZhangWest China School of Public Health, Sichuan University, Chengdu, China.
Shenghua ZhouThe Second Xiangya Hospital of Central South University, Renmin Middle Road 139 #, Changsha, 410011, China. zhoushenghua@csu.edu.cn.ORCID http://orcid.org/0000-0001-5388-7766

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPulsed field ablation (PFA) is an emerging innovative technology for treating paroxysmal atrial fibrillation (PAF), featured by its superior speed, accuracy, and reduced risk to adjacent tissues. The NOVA-AF study aimed to evaluate the efficacy and safety of a novel PFA system equipped with two PFA catheters: a circular PFA catheter and a linear PFA catheter integrating contact force-sensing capability, in patients with symptomatic PAF.

methodsThis prospective, multicenter, single-arm study enrolled 161 patients with symptomatic PAF from seven medical centers in China. The composite primary effectiveness endpoint was defined as freedom from atrial tachyarrhythmia recurrence, device failure, multiple ablations during the blanking period, or antiarrhythmic drug failure during the evaluation period. The primary safety endpoint was the incidence of major adverse events (MAEs) related to the devices or procedures within three months of the procedure.

resultsAll the ablated lesions (100%) were acutely electrically isolated. No patients underwent repeat ablation during the 90-day blanking period. The 12-month Kaplan–Meier estimates for primary effectiveness success and clinical success (absence of symptomatic atrial fibrillation recurrence) were 83.0% (95% confidence interval, 76.2%–88.0%) and 94.9%, respectively. No MAEs occurred.

conclusionThis novel PFA system is effective and safe for the ablation treatment of patients with symptomatic PAF. REGISTRY: Chinese Clinical Trial Registry ( www.chictr.org.cn ), TRN: ChiCTR2400091941, Registration date: Nov 6 2024 (retrospectively registered).

Indexed as

Atrial fibrillationContact forceElectroporationPulmonary vein isolationPulsed field ablation

Identifiers

PMID41817907

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.